As MYD88 and CD79B mutations were the markers of the MCD subtype, one of the four prominent genetic subtypes in DLBCL [17], nearly half (67/148) of the cohort, were classified into the MCD subtype (Fig. 1B). This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.